Inspired by the antiviral activity of known pyrazole-based HIV inhibitors, we screened our in-house library of pyrazole-based compounds to evaluate their in cellulo activity against HIV-1 replication. Two hits with very similar structures appeared from single and multiple-round infection assays to be non-toxic and active in a dose-dependent manner. Chemical expansion of their series allowed an in-depth and consistent structure–activity-relationship study (SAR) to be built. Further ADME evaluation led to the selection of 4-amino-3-cyano-1-(2-benzyloxyphenyl)-1H-pyrazole-5-carboxylate with an advantageous pharmacokinetic profile. Finally, examination of its mode of action revealed that this compound does not belong to the three main classes of anti-HIV drugs, a feature of prime interest in the context of viral resistance.

中文翻译：

---

4-氨基-3-氰基-1-(2-苄氧基苯基)-1H-吡唑-5-羧酸甲酯作为HIV-1复制抑制剂的发现、SAR研究和ADME特性

受已知基于吡唑的 HIV 抑制剂的抗病毒活性的启发，我们筛选了我们内部的基于吡唑的化合物库，以评估它们在纤维素中对 HIV-1 复制的活性。从单轮和多轮感染测定中显示出具有非常相似结构的两个命中是无毒的并且以剂量依赖性方式具有活性。他们系列的化学扩展允许建立深入和一致的结构-活性-关系研究 (SAR)。进一步的 ADME 评估导致选择了 4-amino-3-cyano-1-(2-benzyloxyphenyl)-1 H-pyrazole-5-carboxylate 具有有利的药代动力学特征。最后，对其作用方式的检查表明，该化合物不属于三种主要的抗 HIV 药物，这是在病毒耐药性背景下最令人感兴趣的特征。